Controversies in NSCLC: which second-line strategy after chemo-immunotherapy?

ESMO Open. 2023 Apr;8(2):100879. doi: 10.1016/j.esmoop.2023.100879. Epub 2023 Feb 13.

Authors

L Moliner¹, L Spurgeon¹, R Califano²

Affiliations

¹ Department of Medical Oncology, The Christie Hospital NHS Foundation Trust, Manchester.
² Department of Medical Oncology, The Christie Hospital NHS Foundation Trust, Manchester; Division of Cancer Sciences, The University of Manchester, Manchester, UK. Electronic address: raffaele.califano@nhs.net.

No abstract available

Publication types

Editorial

MeSH terms

Carcinoma, Non-Small-Cell Lung* / drug therapy
Humans
Immunotherapy
Lung Neoplasms* / drug therapy